📊 ENTA Key Takeaways
Is Enanta Pharmaceuticals Inc. (ENTA) a Good Investment?
Enanta is a cash-burning pharmaceutical company with declining revenue (-3.4% YoY) and severe profitability headwinds (-70% net margin, -19.0M negative free cash flow). While the company maintains a strong balance sheet with minimal debt and $34.9M cash, its current burn rate implies only ~1.8 years of runway before requiring external capital or achieving profitability. Lacking visibility into pipeline catalysts, the deteriorating commercial performance and negative operating cash flow signal an unsustainable business model.
Enanta Pharmaceuticals shows weak current operating fundamentals, with declining revenue, deeply negative operating and net margins, and negative free cash flow. However, the company still has a strong liquidity profile, minimal leverage, and a balance sheet that provides time to fund development and absorb losses. The core fundamental picture is mixed: financial health is solid, but profitability and growth quality remain weak.
Enanta Pharmaceuticals Inc. Key Strengths (ENTA)
- Strong balance sheet with minimal leverage (Debt/Equity 0.02x)
- Excellent liquidity position (Current Ratio 3.84x, $34.9M cash on hand)
- Pharmaceutical sector exposure with potential for pipeline-driven turnaround
- Very strong liquidity with 4.44x current and quick ratios
- Low financial leverage with debt/equity of 0.02x and only $2.00M in long-term debt
- Asset base and cash position provide near-term operating flexibility despite ongoing losses
ENTA Stock Risks: Enanta Pharmaceuticals Inc. Investment Risks
- Significant annual cash burn (-$19.0M FCF) with estimated 1.8 year runway before capital constraints
- Declining revenue (-3.4% YoY) indicates loss of market traction and insufficient new product launches
- Severely unprofitable with -70% net margin and -64.6% operating margin; negative operating cash flow signals non-viable core business
- Dependent on successful clinical development and regulatory approval for viability; no evidence of near-term catalysts
- Revenue declined year over year while margins remain deeply negative
- Negative operating cash flow and free cash flow indicate the business is not self-funding
- Negative ROE, ROA, and weak interest coverage reflect poor underlying earnings quality
Key Metrics to Watch
- Revenue growth rate return to positive territory
- Operating cash flow inflection and path to positive FCF
- Cash balance runway and any capital raise announcements
- Pipeline advancement and clinical trial readouts for key programs
- Revenue growth and operating margin improvement
- Operating cash flow burn and cash balance trend
Enanta Pharmaceuticals Inc. (ENTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.84x current ratio provides a solid financial cushion.
ENTA Profit Margin, ROE & Profitability Analysis
ENTA vs Healthcare Sector: How Enanta Pharmaceuticals Inc. Compares
How Enanta Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enanta Pharmaceuticals Inc. Stock Overvalued? ENTA Valuation Analysis 2026
Based on fundamental analysis, Enanta Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enanta Pharmaceuticals Inc. Balance Sheet: ENTA Debt, Cash & Liquidity
ENTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enanta Pharmaceuticals Inc.'s revenue has declined by 61% over the 5-year period, indicating business contraction. The most recent EPS of $-6.38 indicates the company is currently unprofitable.
ENTA Revenue Growth, EPS Growth & YoY Performance
ENTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $14.9M | -$11.9M | $-0.45 |
| Q1 2026 | $17.0M | -$11.9M | $-0.42 |
| Q3 2025 | $18.0M | -$18.3M | $-0.85 |
| Q2 2025 | $14.9M | -$22.3M | $-1.06 |
| Q3 2024 | $18.0M | -$22.7M | $-1.07 |
| Q2 2024 | $17.1M | -$29.0M | $-1.47 |
| Q1 2024 | $17.0M | -$22.3M | $-1.05 |
| Q3 2023 | $18.9M | -$29.0M | $-1.53 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Enanta Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
ENTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enanta Pharmaceuticals Inc. (CIK: 0001177648)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENTA
What is the AI rating for ENTA?
Enanta Pharmaceuticals Inc. (ENTA) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENTA's key strengths?
Claude: Strong balance sheet with minimal leverage (Debt/Equity 0.02x). Excellent liquidity position (Current Ratio 3.84x, $34.9M cash on hand). ChatGPT: Very strong liquidity with 4.44x current and quick ratios. Low financial leverage with debt/equity of 0.02x and only $2.00M in long-term debt.
What are the risks of investing in ENTA?
Claude: Significant annual cash burn (-$19.0M FCF) with estimated 1.8 year runway before capital constraints. Declining revenue (-3.4% YoY) indicates loss of market traction and insufficient new product launches. ChatGPT: Revenue declined year over year while margins remain deeply negative. Negative operating cash flow and free cash flow indicate the business is not self-funding.
What is ENTA's revenue and growth?
Enanta Pharmaceuticals Inc. reported revenue of $35.8M.
Does ENTA pay dividends?
Enanta Pharmaceuticals Inc. does not currently pay dividends.
Where can I find ENTA SEC filings?
Official SEC filings for Enanta Pharmaceuticals Inc. (CIK: 0001177648) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENTA's EPS?
Enanta Pharmaceuticals Inc. has a diluted EPS of $-0.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ENTA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Enanta Pharmaceuticals Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ENTA stock overvalued or undervalued?
Valuation metrics for ENTA: ROE of -21.5% (sector avg: 15%), net margin of -70.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ENTA's AI grade for 2026?
Our dual AI analysis gives Enanta Pharmaceuticals Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENTA's free cash flow?
Enanta Pharmaceuticals Inc.'s operating cash flow is $-18.9M, with capital expenditures of $158.0K. FCF margin is -53.1%.
How does ENTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -70.0% (avg: 12%), ROE -21.5% (avg: 15%), current ratio 3.84 (avg: 2).